- Home
- NDLS vs LVTX Comparison
NDLS vs LVTX Comparison
Compare NDLS & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDLS
- LVTX
- Stock Information
- Founded
- NDLS 1995
- LVTX 2016
- Country
- NDLS United States
- LVTX Netherlands
- Employees
- NDLS N/A
- LVTX N/A
- Industry
- NDLS Restaurants
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- NDLS Consumer Discretionary
- LVTX Health Care
- Exchange
- NDLS Nasdaq
- LVTX Nasdaq
- Market Cap
- NDLS 32.9M
- LVTX 33.9M
- IPO Year
- NDLS 2013
- LVTX 2021
- Fundamental
- Price
- NDLS $0.87
- LVTX $1.43
- Analyst Decision
- NDLS Strong Buy
- LVTX Hold
- Analyst Count
- NDLS 2
- LVTX 3
- Target Price
- NDLS $3.00
- LVTX $1.75
- AVG Volume (30 Days)
- NDLS 234.3K
- LVTX 20.5K
- Earning Date
- NDLS 08-06-2025
- LVTX 08-19-2025
- Dividend Yield
- NDLS N/A
- LVTX N/A
- EPS Growth
- NDLS N/A
- LVTX N/A
- EPS
- NDLS N/A
- LVTX N/A
- Revenue
- NDLS $495,670,000.00
- LVTX $4,990,000.00
- Revenue This Year
- NDLS $5.37
- LVTX N/A
- Revenue Next Year
- NDLS $0.68
- LVTX N/A
- P/E Ratio
- NDLS N/A
- LVTX N/A
- Revenue Growth
- NDLS N/A
- LVTX N/A
- 52 Week Low
- NDLS $0.55
- LVTX $0.85
- 52 Week High
- NDLS $1.83
- LVTX $2.32
- Technical
- Relative Strength Index (RSI)
- NDLS 59.19
- LVTX 63.92
- Support Level
- NDLS $0.80
- LVTX $1.27
- Resistance Level
- NDLS $0.92
- LVTX $1.45
- Average True Range (ATR)
- NDLS 0.07
- LVTX 0.05
- MACD
- NDLS 0.01
- LVTX 0.01
- Stochastic Oscillator
- NDLS 88.89
- LVTX 79.40
About NDLS Noodles & Company
Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.